Cardiac Translational Research Implementation Program (C-TRIP) (P20)

Post Date

December 4th 2008

Application Due Date

May 28th 2009

Funding Opportunity Number

RFA-HL-10-001

CFDA Number(s)

93.837

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $9000000

• Award Range:

  $None - $499999

Grant Description

-Purpose. The National Heart, Lung, and Blood Institute (NHLBI) solicits Stage 1 exploratory planning (P20) applications to the Cardiac Translational Research Implementation Program (C-TRIP).The overall objective of the entire two-staged C-TRIP is to accelerate translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias through the planning and execution of well-designed clinical trials to demonstrate safety and efficacy.Stage 1 exploratory planning (P20) applications will support the planning and development of Stage 2 specialized center (P50) applications that support the conduct of the safety and efficacy trials recommended for support following a second phase of peer review. Subsequent Stage 2 (P50) applications for the conduct of the clinical trials planned and developed during Stage 1 will be solicited at a later time.The to-be-released solicitation for Stage 2 specialized center (P50) applications will be limited to successful Stage 1 applicants. Stage 2 (P50) applications will be anticipated 18 months following the initial award of Stage 1 applications.Support during Stage 2 of C-TRIP is expected to provide up to $1,515,000 direct costs per year for up to five years.Only two-year, Stage 1 (P20) applications are being solicited at this time. -Budget and Project Period. The total project period for the Stage 1 exploratory planning (P20) applications submitted in response to the present C-TRIP announcement is two years.During this period, applicants may request no more than $500,000 per year in direct costs for a maximum of $1,000,000 direct costs. -Mechanism of Support.This FOA for Stage 1 C-TRIP applications will utilize the Exploratory Grants Mechanism (P20).

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-10-001.html